This statistic was assembled from several of AbbVie's annual reports. * Research and development expenses in 2018 increased from 2017, principally due to a 5.1 billion dollars intangible asset impairment charge related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial.
** R&D expenses for 2024 were impacted by the intangible asset impairment charge of 4.5 billion related to emraclidine compared to an intangible asset impairment charge of 630 million in 2023, increased funding to support all stages of the company's pipeline assets and acquisition and integration costs incurred in connection with the ImmunoGen and Cerevel Therapeutics acquisitions, including cash-settled, post-closing expense for employee incentive awards.
In 2025, AbbVie significantly increased its R&D expenditure to 9.1 billion U.S. dollars. Abbot was a U.S.-based global pharmaceutical and healthcare products company, headquartered in Chicago, Illinois. In January 2013, Abbott was separated into two companies: Abbott Laboratories and AbbVie. Abbott Laboratories is now specialized on medical products, while AbbVie is responsible for research-based pharmaceuticals. On May 8, 2020, AbbVie completed the acquisition of Allergan plc.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
AbbVie, & U.S. Securities and Exchange Commission. (February 20, 2026). Research and development expenditure of AbbVie from 2012 to 2025 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 27, 2026, from /statistics/417068/r-and-d-expenditure-of-abbvie/
AbbVie, und U.S. Securities and Exchange Commission. "Research and development expenditure of AbbVie from 2012 to 2025 (in million U.S. dollars)." Chart. February 20, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 27, 2026. /statistics/417068/r-and-d-expenditure-of-abbvie/
AbbVie, U.S. Securities and Exchange Commission. (2026). Research and development expenditure of AbbVie from 2012 to 2025 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 27, 2026. /statistics/417068/r-and-d-expenditure-of-abbvie/
AbbVie, and U.S. Securities and Exchange Commission. "Research and Development Expenditure of Abbvie from 2012 to 2025 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 20 Feb 2026, /statistics/417068/r-and-d-expenditure-of-abbvie/
AbbVie & U.S. Securities and Exchange Commission, Research and development expenditure of AbbVie from 2012 to 2025 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/417068/r-and-d-expenditure-of-abbvie/ (last visited July 27, 2026)
Research and development expenditure of AbbVie from 2012 to 2025 (in million U.S. dollars) [Graph], AbbVie, & U.S. Securities and Exchange Commission, February 20, 2026. [Online]. Available: /statistics/417068/r-and-d-expenditure-of-abbvie/
